The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection
Sponsor: Glaxo Wellcome
A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Glaxo Wellcome and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Glaxo Wellcome
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bay Pines, United States, Birmingham, United States, Charlottesville, United States, Chicago, United States, Detroit, United States, Galveston, United States, Houston, United States, Nashville, United States, Philadelphia, United States, Richmond, United States and 4 more location s